Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Citizens Capital Markets Reiterates Market Outperform on Acrivon Therapeutics, Maintains $17 Price Target

Author: Benzinga Newsdesk | March 26, 2025 07:59am
Citizens Capital Markets analyst Silvan Tuerkcan reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Market Outperform and maintains $17 price target.

Posted In: ACRV


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist